REPRIEVE - A Randomized Trial to Prevent Vascular Events in HIV
||Age 40-75 on ART not receiving a statin
||Double-blind, randomized, placebo-controlled, multicenter efficacy study in 6500 subjects. Primary objective is to determine if pitavastatin prevents major CVD events in HIV
||On ART, age 40-75, CD4 >100, calculated 10-yr CVD risk <10%, LDL <190, no prior stroke/MI/PVD or diabetes, no use of lipid lowering drugs
||Up to 72 months with study visits every 4 months. Compensation provided.
||Bartolo Santos, RN 323-343-8278
Connie Funk, RN 323-343-8282